查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1285776

小細胞肺癌（SCLC）治療市場（治療類型：標靶治療，免疫治療，和化學治療；給藥途徑：口服、腸外和其他） - 2023-2031年全球行業分析、規模、佔有率、成長、趨勢和預測

Small Cell Lung Cancer (SCLC) Therapeutics Market (Therapy Type: Targeted Therapy, Immunotherapy, & Chemotherapy; Route of Administration: Oral, Parenteral, & Others) - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 201 Pages | 商品交期: 2-10個工作天內

價格

小細胞肺癌（SCLC）治療藥物市場- 報告範圍

TMR的全球小細胞肺癌（SCLC）治療劑市場的報告研究了過去以及當前的成長趨勢和機會，以獲得對2023年至2031年預測期間市場指標的寶貴見解。報告提供了2017-2031年全球小細胞肺癌（SCLC）治療藥物市場的收入，以2023年為基準年，2031年為預測年。報告還提供了2023年至2031年全球小細胞肺癌（SCLC）治療藥物市場的年複合成長率（CAGR %）。

本報告是在廣泛的研究後編寫的。一級研究包括大部分的研究工作，分析師與關鍵意見領袖、行業領袖和意見製造者的訪談。二級研究包括參考主要參與者的產品資料、年度報告、新聞稿和相關文件，以了解小細胞肺癌（SCLC）治療藥物市場。

本報告深入研究了全球小細胞肺癌（SCLC）治療藥物市場的競爭格局。在全球小細胞肺癌（SCLC）治療市場運作的主要參與者已經過確認，並進行各種屬性分析。公司概況、財務狀況、近期發展和SWOT是本報告對全球小細胞肺癌（SCLC）治療劑市場參與者的屬性分析。

目錄

第一章：前言

  • 市場定義和範圍
  • 市場細分
  • 主要研究目標
  • 研究重點

第二章：假設和研究方法

第三章：執行摘要：全球市場

第四章：市場概述

  • 簡介
    • 治療類型的定義
    • 行業演變/發展
  • 概述
  • 市場動態
    • 驅動力
    • 限制因素
    • 機會
  • 全球市場分析和預測，2017-2031年

第五章：關鍵洞察力

  • 管線分析
  • 全球及主要國家的疾病流行率和發病率
  • 關鍵的行業事件
  • COVID-19對行業的影響

第六章：全球市場分析和預測：按治療類型分類

  • 介紹和定義
  • 主要研究結果/發展情況
  • 市場價值預測：按治療類型，2017-2031年
    • 靶向治療
    • 免疫療法
    • 化療
  • 市場吸引力：按治療類型分類

第七章：全球市場分析與預測：按藥物類型分類

  • 介紹和定義
  • 主要研究結果/發展情況
  • 市場價值預測：按藥物類型，2017-2031年
    • Atezolizumab
    • Durvalumab
    • Lurbinectedin
    • Pembrolizumab
    • Etoposide
    • Methotrexate
    • Topotecan
    • 其他藥物
  • 市場吸引力：按藥物類型

第八章：全球市場分析與預測：按給藥途徑分類

  • 介紹和定義
  • 主要研究結果/發展情況
  • 市場價值預測：按給藥途徑分類，2017-2031年
    • 口服
    • 腸外
    • 其他途徑
  • 市場吸引力：按給藥途徑分類

第九章：全球市場分析與預測：按配銷通路分類

  • 介紹和定義
  • 主要研究結果/發展情況
  • 市場價值預測：按配銷通路分類，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場吸引力：按配銷通路分類

第十章：全球市場分析與預測：按地區分類

  • 主要研究結果
  • 市場價值預測：按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力：按國家/地區

第11章：北美洲市場分析與預測

  • 簡介
    • 主要發現
  • 市場價值預測：按治療類型，2017-2031年
    • 靶向治療
    • 免疫療法
    • 化療
  • 市場價值預測：按藥物類型，2017 - 2031年
    • Atezolizumab
    • Durvalumab
    • Lurbinectedin
    • Pembrolizumab
    • Etoposide
    • Methotrexate
    • Topotecan
    • 其他藥物
  • 市場價值預測：按給藥途徑，2017 - 2031年
    • 口服
    • 腸外
    • 其他途徑
  • 市場價值預測：按配銷通路分類，2017 - 2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家分類，2017 - 2031年
    • 美國
    • 加拿大
  • 市場吸引力分析
    • 按治療類型
    • 按藥物類型
    • 按給藥途徑分類
    • 按配銷通路分類
    • 按國家分類

第12章：歐洲市場分析和預測

  • 簡介
    • 主要發現
  • 市場價值預測：按治療類型，2017-2031年
    • 靶向治療
    • 免疫療法
    • 化療
  • 市場價值預測：按藥物類型，2017 - 2031年
    • Atezolizumab
    • Durvalumab
    • Lurbinectedin
    • Pembrolizumab
    • Etoposide
    • Methotrexate
    • Topotecan
    • 其他藥物
  • 市場價值預測：按給藥途徑，2017 - 2031年
    • 口服
    • 腸外
    • 其他途徑
  • 市場價值預測：按配銷通路分類，2017 - 2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家分類，2017 - 2031年
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 市場吸引力分析
    • 按治療類型
    • 按藥物類型分類
    • 按給藥途徑分類
    • 按配銷通路分類
    • 按國家分類

第13章：亞太地區市場分析和預測

  • 介紹
    • 主要發現
  • 市場價值預測：按治療類型，2017-2031年
    • 靶向治療
    • 免疫療法
    • 化療
  • 市場價值預測：按藥物類型，2017 - 2031年
    • Atezolizumab
    • Durvalumab
    • Lurbinectedin
    • Pembrolizumab
    • Etoposide
    • Methotrexate
    • Topotecan
    • 其他藥物
  • 市場價值預測：按給藥途徑，2017 - 2031年
    • 口服
    • 腸外
    • 其他途徑
  • 市場價值預測：按配銷通路分類，2017 - 2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家分類，2017 - 2031年
    • 中國
    • 日本
    • 印度
    • 澳洲和新西蘭
    • 亞太其他地區
  • 市場吸引力分析
    • 按治療類型
    • 按藥物類型
    • 按給藥途徑分類
    • 按配銷通路
    • 按國家分類

第十四章：拉丁美洲市場分析和預測

  • 簡介
    • 主要發現
  • 市場價值預測：按治療類型，2017-2031年
    • 靶向治療
    • 免疫療法
    • 化療
  • 市場價值預測：按藥物類型，2017 - 2031年
    • Atezolizumab
    • Durvalumab
    • Lurbinectedinin)
    • Pembrolizumab
    • Etoposide
    • Methotrexate
    • Topotecan
    • 其他藥物
  • 市場價值預測：按給藥途徑，2017 - 2031年
    • 口服
    • 腸外
    • 其他途徑
  • 市場價值預測：按配銷通路，2017 - 2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家分類，2017 - 2031年
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 市場吸引力分析
    • 按治療類型
    • 按藥物類型
    • 按給藥途徑分類
    • 按配銷通路
    • 按國家分類

第15章：中東和非洲市場分析和預測

  • 簡介
    • 主要發現
  • 市場價值預測：按治療類型，2017-2031年
    • 靶向治療
    • 免疫療法
    • 化療
  • 市場價值預測：按藥物類型，2017 - 2031年
    • Atezolizumab
    • Durvalumab
    • Lurbinectedin
    • Pembrolizumab
    • Etoposide
    • Methotrexate
    • Topotecan
    • 其他藥物
  • 市場價值預測：按給藥途徑，2017 - 2031年
    • 口服
    • 腸外
    • 其他途徑
  • 市場價值預測：按配銷通路，2017 - 2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家分類，2017 - 2031年
    • 海灣合作理事會國家
    • 南非
    • 中東和非洲其他地區
  • 市場吸引力分析
    • 按治療類型
    • 按藥物類型分類
    • 按給藥途徑分類
    • 按配銷通路
    • 按國家分類

第16章：競爭格局

  • 市場參與者- 競爭矩陣（按公司的層級和規模分類）
  • 按公司分類的市場佔有率分析（2021年）
  • 公司簡介
    • AstraZeneca plc
    • Dr. Reddy's Laboratories, Inc.
    • F. Hoffmann La-Roche Ltd.
    • GSK plc
    • Jazz Pharmaceuticals plc
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
Product Code: TMRGL49311

Small Cell Lung Cancer (SCLC) Therapeutics Market - Scope of Report

TMR's report on the global Small Cell Lung Cancer (SCLC) Therapeutics Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Small Cell Lung Cancer (SCLC) Therapeutics Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Small Cell Lung Cancer (SCLC) Therapeutics Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Small Cell Lung Cancer (SCLC) Therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Small Cell Lung Cancer (SCLC) Therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Small Cell Lung Cancer (SCLC) Therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Small Cell Lung Cancer (SCLC) Therapeutics market.

The report delves into the competitive landscape of the global Small Cell Lung Cancer (SCLC) Therapeutics market. Key players operating in the global Small Cell Lung Cancer (SCLC) Therapeutics Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Small Cell Lung Cancer (SCLC) Therapeutics Market profiled in this report.

Key Questions Answered in Global Small Cell Lung Cancer (SCLC) Therapeutics Market Report:

  • What is the sales/revenue generated by Small Cell Lung Cancer (SCLC) Therapeutics across all regions during the forecast period?
  • What are the opportunities in the global Small Cell Lung Cancer (SCLC) Therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Small Cell Lung Cancer (SCLC) Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global Small Cell Lung Cancer (SCLC) Therapeutics Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Small Cell Lung Cancer (SCLC) Therapeutics Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Small Cell Lung Cancer (SCLC) Therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Small Cell Lung Cancer (SCLC) Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Therapy Type Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, 2017 - 2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Disease Prevalence & Incidence Rate globally with key countries
  • 5.3. Key Industry Events
  • 5.4. COVID-19 Impact on Industry

6. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Therapy Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Therapy Type, 2017 - 2031
    • 6.3.1. Targeted Therapy
    • 6.3.2. Immunotherapy
    • 6.3.3. Chemotherapy
  • 6.4. Market Attractiveness, by Therapy Type

7. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Drug Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Drug Type, 2017 - 2031
    • 7.3.1. Atezolizumab
    • 7.3.2. Durvalumab
    • 7.3.3. Lurbinectedin
    • 7.3.4. Pembrolizumab
    • 7.3.5. Etoposide
    • 7.3.6. Methotrexate
    • 7.3.7. Topotecan
    • 7.3.8. Others
  • 7.4. Market Attractiveness, by Drug Type

8. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Others
  • 8.4. Market Attractiveness, by Route of Administration

9. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness, by Distribution Channel

10. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Country/Region

11. North America Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Therapy Type, 2017 - 2031
    • 11.2.1. Targeted Therapy
    • 11.2.2. Immunotherapy
    • 11.2.3. Chemotherapy
  • 11.3. Market Value Forecast, by Drug Type, 2017 - 2031
    • 11.3.1. Atezolizumab
    • 11.3.2. Durvalumab
    • 11.3.3. Lurbinectedin
    • 11.3.4. Pembrolizumab
    • 11.3.5. Etoposide
    • 11.3.6. Methotrexate
    • 11.3.7. Topotecan
    • 11.3.8. Others
  • 11.4. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 11.4.1. Oral
    • 11.4.2. Parenteral
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast, by Country, 2017 - 2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Therapy Type
    • 11.7.2. By Drug Type
    • 11.7.3. By Route of Administration
    • 11.7.4. By Distribution Channel
    • 11.7.5. By Country

12. Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Therapy Type, 2017 - 2031
    • 12.2.1. Targeted Therapy
    • 12.2.2. Immunotherapy
    • 12.2.3. Chemotherapy
  • 12.3. Market Value Forecast, by Drug Type, 2017 - 2031
    • 12.3.1. Atezolizumab
    • 12.3.2. Durvalumab
    • 12.3.3. Lurbinectedin
    • 12.3.4. Pembrolizumab
    • 12.3.5. Etoposide
    • 12.3.6. Methotrexate
    • 12.3.7. Topotecan
    • 12.3.8. Others
  • 12.4. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 12.4.1. Oral
    • 12.4.2. Parenteral
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Retail Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast, by Country, 2017 - 2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Therapy Type
    • 12.7.2. By Drug Type
    • 12.7.3. By Route of Administration
    • 12.7.4. By Distribution Channel
    • 12.7.5. By Country

13. Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Therapy Type, 2017 - 2031
    • 13.2.1. Targeted Therapy
    • 13.2.2. Immunotherapy
    • 13.2.3. Chemotherapy
  • 13.3. Market Value Forecast, by Drug Type, 2017 - 2031
    • 13.3.1. Atezolizumab
    • 13.3.2. Durvalumab
    • 13.3.3. Lurbinectedin
    • 13.3.4. Pembrolizumab
    • 13.3.5. Etoposide
    • 13.3.6. Methotrexate
    • 13.3.7. Topotecan
    • 13.3.8. Others
  • 13.4. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 13.4.1. Oral
    • 13.4.2. Parenteral
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Retail Pharmacies
    • 13.5.3. Online Pharmacies
  • 13.6. Market Value Forecast, by Country, 2017 - 2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Therapy Type
    • 13.7.2. By Drug Type
    • 13.7.3. By Route of Administration
    • 13.7.4. By Distribution Channel
    • 13.7.5. By Country

14. Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Therapy Type, 2017 - 2031
    • 14.2.1. Targeted Therapy
    • 14.2.2. Immunotherapy
    • 14.2.3. Chemotherapy
  • 14.3. Market Value Forecast, by Drug Type, 2017 - 2031
    • 14.3.1. Atezolizumab
    • 14.3.2. Durvalumab
    • 14.3.3. Lurbinectedin
    • 14.3.4. Pembrolizumab
    • 14.3.5. Etoposide
    • 14.3.6. Methotrexate
    • 14.3.7. Topotecan
    • 14.3.8. Others
  • 14.4. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 14.4.1. Oral
    • 14.4.2. Parenteral
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Retail Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast, by Country, 2017 - 2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Therapy Type
    • 14.7.2. By Drug Type
    • 14.7.3. By Route of Administration
    • 14.7.4. By Distribution Channel
    • 14.7.5. By Country

15. Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Therapy Type, 2017 - 2031
    • 15.2.1. Targeted Therapy
    • 15.2.2. Immunotherapy
    • 15.2.3. Chemotherapy
  • 15.3. Market Value Forecast, by Drug Type, 2017 - 2031
    • 15.3.1. Atezolizumab
    • 15.3.2. Durvalumab
    • 15.3.3. Lurbinectedin
    • 15.3.4. Pembrolizumab
    • 15.3.5. Etoposide
    • 15.3.6. Methotrexate
    • 15.3.7. Topotecan
    • 15.3.8. Others
  • 15.4. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 15.4.1. Oral
    • 15.4.2. Parenteral
    • 15.4.3. Others
  • 15.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 15.5.1. Hospital Pharmacies
    • 15.5.2. Retail Pharmacies
    • 15.5.3. Online Pharmacies
  • 15.6. Market Value Forecast, by Country, 2017 - 2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Therapy Type
    • 15.7.2. By Drug Type
    • 15.7.3. By Route of Administration
    • 15.7.4. By Distribution Channel
    • 15.7.5. By Country

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 16.2. Market Share Analysis By Company (2021)
  • 16.3. Company Profiles
    • 16.3.1. AstraZeneca plc
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Test Type Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Dr. Reddy's Laboratories, Inc.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Test Type Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. F. Hoffmann La-Roche Ltd.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Test Type Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. GSK plc
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Test Type Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Jazz Pharmaceuticals plc
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Test Type Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Merck & Co., Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Test Type Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Novartis AG
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Test Type Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Pfizer Inc.
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Test Type Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview

List of Tables

  • Table 01: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
  • Table 02: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 03: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 04: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 05: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
  • Table 08: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 09: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 10: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 11: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 12: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
  • Table 13: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 14: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 15: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
  • Table 18: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 19: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 20: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 22: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
  • Table 23: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 24: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 25: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 26: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 27: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
  • Table 28: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 29: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 30: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share, by Therapy Type, 2022
  • Figure 03: Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share, by Drug Type, 2022
  • Figure 04: Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share, by Route of Administration, 2022
  • Figure 05: Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share, by Distribution Channel, 2022
  • Figure 06: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2022 and 2031
  • Figure 07: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 08: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Targeted Therapy, 2017-2031
  • Figure 09: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Immunotherapy, 2017-2031
  • Figure 10: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Chemotherapy, 2017-2031
  • Figure 11: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 12: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 13: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Atezolizumab, 2017-2031
  • Figure 14: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Durvalumab, 2017-2031
  • Figure 15: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Lurbinectedin, 2017-2031
  • Figure 16: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Pembrolizumab, 2017-2031
  • Figure 17: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Etoposide, 2017-2031
  • Figure 18: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Methotrexate, 2017-2031
  • Figure 19: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Topotecan, 2017-2031
  • Figure 20: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Others, 2017-2031
  • Figure 21: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 22: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 23: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Oral, 2017-2031
  • Figure 24: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Parenteral, 2017-2031
  • Figure 25: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Others, 2017-2031
  • Figure 26: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 27: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 28: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Hospital Pharmacies, 2017-2031
  • Figure 29: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 30: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Online Pharmacies, 2017-2031
  • Figure 31: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 32: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 33: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 34: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 35: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 36: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2022 and 2031
  • Figure 37: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 38: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 39: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 40: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 41: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 42: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 43: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 44: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 45: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 46: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 47: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2022 and 2031
  • Figure 48: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 49: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 50: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 51: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 52: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 53: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 54: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 55: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 56: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 57: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 58: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2022 and 2031
  • Figure 59: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 60: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 61: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 62: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 63: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 64: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 65: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 65: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 67: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 68: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 69: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2022 and 2031
  • Figure 70: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 71: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 71: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 73: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 74: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 75: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 76: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 77: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 78: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 79: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 80: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2022 and 2031
  • Figure 81: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 82: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 83: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 84: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 85: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 86: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 87: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 88: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Share Analysis, by Company, 2022